Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
CAMBRIDGE, Mass., March 08, 2017 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its fourth quarter and full year 2016 financial results conference call and live webcast scheduled for Wednesday, March 15, 2017 at 8:30 a.m. EDT.
The live call may be accessed by dialing (877) 851-3834 for domestic callers or +1 (631) 291-4595 for international callers, and referencing conference ID number 83618016. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the CNS. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company’s pipeline focuses on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Friedreich’s ataxia, Huntington’s disease, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Investor Relations: Matt Osborne Head of Investor Relations & Corporate Communications 857-259-5353 [email protected] Media: Josephine Butler Pure Communications, Inc. 910-337-0707 [email protected]
